Rituximab and ▼abatacept for rheumatoid arthritis

Drug and Therapeutics Bulletin

Volumn 46, Issue 8, 2008, Pages 57-61

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANALGESIC AGENT; ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTHRALGIA; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BRONCHOSPASM; CLINICAL TRIAL; CONJUNCTIVITIS; COUGHING; DEPRESSION; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEVER; GASTRITIS; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; JOINT STIFFNESS; LIFE EXPECTANCY; LIVER FUNCTION TEST; LUNG ASPERGILLOSIS; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PHYSIOTHERAPY; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; QUALITY OF LIFE; RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; VERTIGO; VISUAL ANALOG SCALE; ADULT; ARTICLE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES;

EID: 58149260843     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2008.07.0017     Document Type: Review

References (28)

1. National Institute for Health and Clinical Excellence, 2007. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis [online]. Available: http://www.nice.org.uk/nicemedia/pdf/ TA130guidance.pdf [Accessed 17 July 2008].
2. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology 2005; 44 (suppl 2): ii3-ii7.
3. DAS-score.nl: Disease Activity Score in rheumatoid arthritis [online]. Netherlands. Avaliable: http://www.das-score.nl/www.das-score.nl/ index.html [Accessed 17 July 2008].
4. Felson DT et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
5. Edwards JC et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
6. Smolen JS et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-50.
7. Luqmani R et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first 2 years). Rheumatology 2006; 45: 1167-9.
8. Combination therapy for early rheumatoid arthritis. DTB 2006; 44: 81-5.
9. Etanercept and infliximab for rheumatoid arthritis. DTB 2001; 39: 49-52.
10. Dixon WG et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
11. Hyrich KL et al. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results form a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
12. National Institute for Health and Clinical Excellence, 2008. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appraisal consultation document [online]. Available: http://www.nice.org.uk/guidance/ index.jsp?action=article&o=40465 [Accessed 17 July 2008].
13. Genovese MC et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy. Ann Rheum Dis 2007; doi:10.1136/ard.2007.074773.
14. Keystone E et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896-908.
15. Mabthera 100mg and 500mg concentrate for solution for infusion. Summary of product characteristics, EU. Roche Registration Limited, May 2007.
16. Orencia 250mg powder for concentrate for solution for infusion. Summary of product characteristics, EU. Bristol-Myers Squibb Pharma EEIG, May 2007.
17. Emery P et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
18. Cohen SB et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
19. Roche Pharmaceuticals Ltd. Important drug warning letter. 2 April 2007.
20. National Institute for Health and Clinical Excellence, 2007. Rituximab for the treatment of rheumatoid arthritis [online]. Available: http://www.nice.org.uk/ nicemedia/pdf/TA126guidance.pdf [Accessed 17 July 2008].
21. National Institute for Health and Clinical Excellence, 2007. Scope: rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults [online]. Available: http://www.nice.org.uk/nicemedia/pdf/RAScope. pdf [Accessed 17 July 2008].
22. Kremer JM et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-15.
23. Kremer JM et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-71.
24. Kremer JM et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865-76.
25. Genant HK et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2007; doi:10.1136/ard.2007.085084.
26. Genovese MC et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 1114-23.
27. Schiff M et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67: 1096-103.
28. National Institute for Health and Clinical Excellence, 2008. Abatacept for the treatment of rheumatoid arthritis [online]. Available: http://www.nice.org.uk/ nicemedia/pdf/TA141guidance.pdf [Accessed 17 July 2008].